Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

The association between haemorrhage and markers of endothelial insufficiency and inflammation in patients with hypoproliferative thrombocytopenia: a cohort study.

Ypma PF, van Geloven N, Kerkhoffs JLH, Te Boekhorst P, Zwaginga JJ, Beckers EAM, Brand A, van der Meer PF, Eikenboom JCJ.

Br J Haematol. 2019 Nov 15. doi: 10.1111/bjh.16291. [Epub ahead of print]

PMID:
31730713
2.

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.

Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S.

Haematologica. 2019 Nov;104(11):2274-2282. doi: 10.3324/haematol.2018.213900. Epub 2019 Mar 28.

3.

The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions.

Netelenbos T, Massey E, de Wreede LC, Harding K, Hamblin A, Sekhar M, Li A, Ypma PF, Ball L, Zwaginga JJ, Stanworth SJ.

Transfusion. 2019 Jan;59(1):160-168. doi: 10.1111/trf.14994. Epub 2018 Nov 1.

PMID:
30383912
4.

Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial.

van der Meer PF, Ypma PF, van Geloven N, van Hilten JA, van Wordragen-Vlaswinkel RJ, Eissen O, Zwaginga JJ, Trus M, Beckers EAM, Te Boekhorst P, Tinmouth A, Lin Y, Hsia C, Lee D, Norris PJ, Goodrich RP, Brand A, Hervig T, Heddle NM, van der Bom JG, Kerkhoffs JH.

Blood. 2018 Jul 12;132(2):223-231. doi: 10.1182/blood-2018-02-831289. Epub 2018 May 17.

PMID:
29773572
5.

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.

Atiq F, Meijer K, Eikenboom J, Fijnvandraat K, Mauser-Bunschoten EP, van Galen KPM, Nijziel MR, Ypma PF, de Meris J, Laros-van Gorkom BAP, van der Bom JG, de Maat MP, Cnossen MH, Leebeek FWG; WiN study group.

Br J Haematol. 2018 Jul;182(1):93-105. doi: 10.1111/bjh.15277. Epub 2018 May 16.

6.

Randomised controlled trial protocol to evaluate a fixed dose prothrombin complex concentrate against the variable dose in vitamin K antagonist related bleeding (PROPER3).

Abdoellakhan RA, Khorsand N, Van Hest RM, Veeger N, Ter Avest E, Ypma PF, Faber LM, Meijer K.

BMJ Open. 2018 Mar 14;8(3):e020764. doi: 10.1136/bmjopen-2017-020764.

7.

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.

Nijhof IS, Franssen LE, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NWCJ.

Blood. 2016 Nov 10;128(19):2297-2306. doi: 10.1182/blood-2016-07-729236. Epub 2016 Sep 19.

PMID:
27647864
8.

A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial.

Ypma PF, van der Meer PF, Heddle NM, van Hilten JA, Stijnen T, Middelburg RA, Hervig T, van der Bom JG, Brand A, Kerkhoffs JL; PREPAReS Study Group.

BMJ Open. 2016 Jan 27;6(1):e010156. doi: 10.1136/bmjopen-2015-010156.

9.

Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma.

Meenhuis A, van Vliet R, Hudig F, Ypma PF, Schipperus MR, Hollestelle MJ.

Clin Case Rep. 2015 Jul;3(7):587-93. doi: 10.1002/ccr3.294. Epub 2015 May 25.

10.

Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor.

Bilgin YM, Visser O, Beckers EA, te Boome LC, Huisman C, Ypma PF, Croockewit AJ, Netelenbos T, Kramer EP, de Greef GE.

Transfusion. 2015 May;55(5):1021-7. doi: 10.1111/trf.12979. Epub 2014 Dec 30.

PMID:
25641128
11.

von Willebrand disease and aging: an evolving phenotype.

Sanders YV, Giezenaar MA, Laros-van Gorkom BA, Meijer K, van der Bom JG, Cnossen MH, Nijziel MR, Ypma PF, Fijnvandraat K, Eikenboom J, Mauser-Bunschoten EP, Leebeek FW; WiN study group.

J Thromb Haemost. 2014 Jul;12(7):1066-75. doi: 10.1111/jth.12586.

12.

Large volume apheresis: electrolyte imbalance and loss of platelets; watch for clinically relevant disturbances.

Ypma PF, Muradin A, Kerkhoffs JL.

Transfus Apher Sci. 2013 Apr;48(2):149. doi: 10.1016/j.transci.2013.02.011. Epub 2013 Mar 16. No abstract available.

PMID:
23809809
13.

Measuring clinical bleeding using a standardized daily report form and a computer algorithm for adjudication of WHO bleeding grades.

Middelburg RA, Ypma PF, van der Meer PF, van Wordragen-Vlaswinkel RJ, Eissen O, Kerkhoffs JL.

Vox Sang. 2013 Aug;105(2):144-9. doi: 10.1111/vox.12030. Epub 2013 Mar 20.

PMID:
23517250
14.

Cardiac catheterization and intervention in haemophilia patients: prospective evaluation of the 2009 institutional guideline.

Tuinenburg A, Damen SA, Ypma PF, Mauser-Bunschoten EP, Voskuil M, Schutgens RE.

Haemophilia. 2013 May;19(3):370-7. doi: 10.1111/hae.12109. Epub 2013 Mar 18.

PMID:
23496171
15.

The observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting.

Ypma PF, Kerkhoffs JL, van Hilten JA, Middelburg RA, Coccoris M, Zwaginga JJ, Beckers EM, Fijnheer R, van der Meer PF, Brand A.

Transfus Med. 2012 Dec;22(6):426-31. doi: 10.1111/j.1365-3148.2012.01193.x. Epub 2012 Oct 5.

PMID:
23036067
16.

An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies.

Khorsand N, Veeger NJ, van Hest RM, Ypma PF, Heidt J, Meijer K.

Haematologica. 2012 Oct;97(10):1501-6. doi: 10.3324/haematol.2012.063701. Epub 2012 Apr 4.

17.

Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety.

Hofstra JJ, Kleine Budde I, van Twuyver E, Choi G, Levi M, Leebeek FW, de Monchy JG, Ypma PF, Keizer RJ, Huitema AD, Strengers PF.

Clin Immunol. 2012 Mar;142(3):280-90. doi: 10.1016/j.clim.2011.11.005. Epub 2011 Nov 16.

PMID:
22197071
18.

Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis.

Tuinenburg A, Rutten A, Kavousi M, Leebeek FW, Ypma PF, Laros-van Gorkom BA, Nijziel MR, Kamphuisen PW, Mauser-Bunschoten EP, Roosendaal G, Biesma DH, van der Lugt A, Hofman A, Witteman JC, Bots ML, Schutgens RE.

Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):799-804. doi: 10.1161/ATVBAHA.111.238162. Epub 2011 Dec 15.

PMID:
22173226
19.

Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease.

De Wee EM, Knol HM, Mauser-Bunschoten EP, van der Bom JG, Eikenboom JC, Fijnvandraat K, De Goede-Bolder A, Laros-van Gorkom B, Ypma PF, Zweegman S, Meijer K, Leebeek FW; WiN study group.

Thromb Haemost. 2011 Nov;106(5):885-92. doi: 10.1160/TH11-03-0180. Epub 2011 Sep 22.

PMID:
21947221
20.

Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma.

Ypma PF, Wijermans PW, Koppen H, Sillevis Smitt PA.

Neth J Med. 2006 Jul-Aug;64(7):243-7.

21.

[Diagnostic image (97). A woman with septicemia due to the small intestinal infarction].

Kummer JA, Ypma PF.

Ned Tijdschr Geneeskd. 2002 Jul 20;146(29):1368. Dutch.

PMID:
12162175

Supplemental Content

Support Center